BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 29630550)

  • 1. Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.
    Stonnington CM; Chen Y; Savage CR; Lee W; Bauer RJ; Sharieff S; Thiyyagura P; Alexander GE; Caselli RJ; Locke DEC; Reiman EM; Chen K
    J Alzheimers Dis; 2018; 63(2):603-615. PubMed ID: 29630550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding.
    Stonnington CM; Wu J; Zhang J; Shi J; Bauer Iii RJ; Devadas V; Su Y; Locke DEC; Reiman EM; Caselli RJ; Chen K; Wang Y;
    J Alzheimers Dis; 2021; 81(1):209-220. PubMed ID: 33749642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
    Inui Y; Ito K; Kato T;
    J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.
    Paranjpe MD; Chen X; Liu M; Paranjpe I; Leal JP; Wang R; Pomper MG; Wong DF; Benzinger TLS; Zhou Y;
    Neuroimage Clin; 2019; 22():101795. PubMed ID: 30991617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares.
    Chen K; Ayutyanont N; Langbaum JB; Fleisher AS; Reschke C; Lee W; Liu X; Alexander GE; Bandy D; Caselli RJ; Reiman EM
    Neuroimage; 2012 May; 60(4):2316-22. PubMed ID: 22348880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
    Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
    J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
    Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
    Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and
    Riederer I; Bohn KP; Preibisch C; Wiedemann E; Zimmer C; Alexopoulos P; Förster S
    Radiology; 2018 Jul; 288(1):198-206. PubMed ID: 29762090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
    Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
    Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
    Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
    J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.